News

Rucaparib Receives Breakthrough Therapy Designation from FDA

Rucaparib Receives Breakthrough Therapy Designation from FDA

April 14, 2015

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough … Continued

Research

Rachel Zoe and Molly Sims Return to Host Ovarian Cancer Res...

Rachel Zoe and Molly Sims Return to Host Ovarian Cancer Research Fund’s 2nd Annual Super Saturday LA

April 14, 2015

Designer Charity Sale Offers Day-Long Luxury Experiences for the Whole Family Los Angeles, CA (April 14, 2015) – Rachel Zoe and Rodger Berman with Molly Sims and Scott Stuber will return to host Ovarian Cancer Research Fund’s (OCRF) 2nd Annual Super Saturday LA. The day-long designer charity sale, now held annually in Los Angeles as … Continued

Events

OCRF Now Accepting Applications for 2016 Research Grants

OCRF Now Accepting Applications for 2016 Research Grants

April 7, 2015

We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.

OCRA News

The New York Times Publishes OCRF’s Letter to the Editor 3/...

The New York Times Publishes OCRF’s Letter to the Editor 3/30/15

April 5, 2015

In response to the “Angelina Jolie Pitt: Diary of a Surgery,” Op-Ed, published in The New York Times on March 24, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, reminding readers that there is still no early detection method for ovarian cancer. We’re grateful to once again have the … Continued

OCRA News

Microenvironment Regulates Tumor Suppressor miRNA

Microenvironment Regulates Tumor Suppressor miRNA

April 2, 2015

(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued

Research

Population Distribution of Lifetime Risk of Ovarian Cancer ...

Population Distribution of Lifetime Risk of Ovarian Cancer in the US

April 1, 2015

(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population.  In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued

Research

Our Response to Angelina

Our Response to Angelina

March 30, 2015

Angelina Jolie Pitt recently announced that she has had her ovaries and fallopian tubes removed in order to reduce her risk of ovarian cancer. Ms. Jolie Pitt had previous shared that she has a mutation in the BRCA gene, which increases her risk of breast and ovarian cancers. The Alliance received many calls and requests … Continued

OCRA News

Intraperitoneal Chemo Associated with Long-Term Survival Ad...

Intraperitoneal Chemo Associated with Long-Term Survival Advantage

March 27, 2015

(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer.  The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued

Research

Partner Member Profile: Ovarian Cancer Alliance of Greater ...

Partner Member Profile: Ovarian Cancer Alliance of Greater Cincinnati

March 27, 2015

The Ovarian Cancer Alliance of Greater Cincinnati (OCAGC) became a Partner Member of the Alliance in October 2010. “It’s been a very positive partnership,” says Martha Farr, an ovarian cancer survivor and co-chair of OCAGC’s Board of Trustees. The group started almost a decade ago, hosting an annual walk to raise awareness. Eventually, the volunteers … Continued

Community

Decisions on a Knife-Edge: Risks and Benefits of Fallopian ...

Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal

March 20, 2015

(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer.  Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women.  Yet it’s not … Continued

Research

Tailored Surgical Approach Leads to Better Outcomes in Ovar...

Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer

March 10, 2015

(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued

Research

Ovarian Cancer Research Fund and National Sponsor QVC Expan...

Ovarian Cancer Research Fund and National Sponsor QVC Expand Woman to Woman Program

February 23, 2015

Gynecologic Cancer Patients to Receive New Support in Baltimore, MD and Portland, OR WEST CHESTER, Pa (February 23, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC® today announced two new Woman to Woman grant recipients: Mercy Medical Center in Baltimore, MD, and Oregon Health and Science University in Portland, OR. The new sites are part … Continued

OCRA News